Results 61 to 70 of about 17,554 (214)

POST-ISCHEMIC TREATMENT WITH CANDESARTAN PROTECTS FROM CEREBRAL ISCHEMIC REPERFUSION INJURY IN NORMOTENSIVE RAT [PDF]

open access: yes
Large body of evidences has indicated that the renin – angiotensin system (RAS) and its effector peptide Angiotensin II may be involved in the pathophysiology of stroke.
نوری, محمد   +1 more
core  

Formulation, Evaluation of Candesartan Cileexitil Fast Disintegrating Immediate Release Tablets [PDF]

open access: yes, 2021
AIM OF THE STUDY: Fast deteriorating tablets (FDTs) have gotten regularly expanding request amid the most recent decade, and the field has turned into a quickly developing territory in the pharmaceutical business. Oral delivery of drugs via conventional
Moulesswaran, S
core  

Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome

open access: yes, 2010
Kanako Bokuda1, Atsuhiro Ichihara1,2, Mariyo Sakoda1, Asako Mito1, Kenichiro Kinouchi1, Hiroshi Itoh11Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; 2Department of Endocrinology and Anti-Aging Medicine, Keio University
Mariyo Sakoda   +3 more
core  

Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility

open access: yes, 2009
Thomas Mengden1, Sakir Uen1, Peter Bramlage21Centre of Vascular Medicine, Herz- und Gefäß-Campus, Bad Nauheim, Germany; 2Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, GermanyAbstract: Hypertension treatment and ...
Thomas Mengden   +2 more
core  

Fibrillatory rate response to candesartan in persistent atrial fibrillation.

open access: yes, 2008
Introduction Angiotensin-receptor blockers may exert favourable anti-arrhythmic effects in atrial fibrillation (AF), but their mechanisms are not fully understood.
Stridh, Martin   +6 more
core   +1 more source

Exploring the role of the membrane bilayer in the recognition of candesartan by its GPCR AT1 receptor.

open access: yesBiochimica et Biophysica Acta - Biomembranes, 2019
Cardiovascular diseases and hypertension in particular are major health risks worldwide and the improvement on their treatment will be beneficial for the human health.
S. Kiriakidi   +4 more
semanticscholar   +1 more source

Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension

open access: yes, 2012
Ola Granström,1 Lars-Åke Levin,2 Martin Henriksson11AstraZeneca Nordic, Södertälje, 2Center for Medical Technology Assessment, Linköping University, Linköping, SwedenBackground: Although angiotensin ...
Levin LA   +2 more
core  

ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN OBAT HIPERTENSI AMLODIPIN & CANDESARTAN PADA PASIEN HIPERTENSI DI KLINIK MERAH PUTIH UNGARAN [PDF]

open access: yes, 2023
Hipertensi merupakan penyakit degeneratif yang memiliki risiko morbiditas dan mortalitas tinggi yang membutuhkan perawatan jangka panjang. Pembiayaan kesehatan di Indonesia semakin meningkat, maka perlu dilakukan analisis efektivitas biaya agar dapat ...
Ayu Kusuma Wardani, Annisa
core  

Perbandingan Efektivitas Terapi Kombinasi (Candesartan Dengan Amlodipine) dan (Candesartan Dengan Nifedipine) Pada Pasien Hipertensi Di RS Lavalette Malang

open access: yes
Hipertensi merupakan suatu kondisi dimana seseorang mengalami kenaikan tekanan darah. Penelitian ini bertujuan untuk membandingkan efektivitas kombinasi candesartan dengan amlodipine dan candesartan dengan nifedipine dalam menurunkan tekanan darah. Jenis
Permata, Agung   +3 more
core   +1 more source

Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy

open access: yes, 2008
Giorgio L Colombo1, Mauro Caruggi2, Chiara Ottolini3, Aldo P Maggioni41S.A.V.E. Studi Analisi Valutazioni Economiche, Milano, Italy; 2Università degli Studi dell’Insubria, Varese, Italy;3Azienda Ospedaliera di Busto Arsizio, Varese, Italy ...
Chiara Ottolini   +3 more
core  

Home - About - Disclaimer - Privacy